ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ARTBIO-$132M-Funding

More Like This

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

PR Newswire associated0

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

Business Wire logo

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors